OASIS, The Online Abstract Submission System
Print this Page for Your Records
Pagina 1 di 2
Close Window
Control/Tracking Number: 2016-T-847-EANM Activity: Technologist Programme Current Date/Time: 4/22/2016 9:43:48 AM Myocardial perfusion imaging using dedicated CZT-SPECT: acquisition time optimization
Author Block: L. Camoni1, G. Damini2, A. Fierro3, G. Zobbio2, R. Giubbini1; 1
Univesity and Spedali Civili of Brescia, BRESCIA, ITALY, 2Univesity of Brescia, BRESCIA,
ITALY, 3Spedali Civili of Brescia, BRESCIA, ITALY. Abstract: Aim: Aim of this study was to evaluate if time reduction of double dose rest acquisition during single day MPI by CZT SPECT can influence the Summed Rest Score (SRS) Material and methods: Single-day stress-rest Gated-SPECT with 185+370 Mbq of Tclabeled compounds wer eperformed using a CZT-based gammacamera (GE D530Alcyone) in 100 patients, randomly selected. The standard acquisition time was 9 minutes for both stress and rest acquisitions. The rest acquisition was retrospectly reconstructed by list-data as a 4 minutes and 30 seconds acquisition. The quantitative data obtained after SPECT reconstructions were evaluated by QPSv2009 using a 17 segment model. The SRS was obtained for the entire LV and from each coronary territory: LAD, LCX and RCA. Statistical analysis was performed using SPSS v.21 (IBM Corp., Armonk, NY, USA) by Wilcoxon paired test. Results: The data were expressed as means ± standard deviation. The 9 minutes SRS was 2.65±4.4; LAD 1.58±2.9; LCX 0.57±1.6; RCA 0.5±1.3; conversely the 4’30” minutes SRS was 2.81±4.57; LAD 1.67±2.9; LCX 0.58±1.7; RCA 0.6±1.4. p=ns. The SSS was 4,93±5.7 and the SDS for 9 minutes and half-time were respectively 2.59±2.77 and 2.49±2.76. p=ns. Conclusion: after injection of 185+370 MBq of Tc-labelled compounds for stress/rest MPI, rest acquisition can be shortened as half time acquisition does not affect SRS and SDS results. :
Topic (Complete): 404 Imaging Systems Biology Track (Complete): Disclosures (Complete): I or one of my co-authors (specify name/position/company) hold a position as an employee, consultant, assessor or advisor for a pharmaceutical, device or
http://www.abstractsonline.com/cSubmit/SubmitPrinterFriendlyVersion.asp?ControlK... 22/04/2016
OASIS, The Online Abstract Submission System
Pagina 2 di 2
biotechnology company: : Nothing to disclose I or one of my co-authors (specify name/position/company) receive support from a pharmaceutical, device or biotechnology company (please specify which project and whether support is in kind or monetary): : Nothing to disclose I or one of my co-authors (specify name/position/company) hold property rights/patents for (radio)pharmaceuticals, medical devices or medical consulting firms: : Nothing to disclose I or one of my co-authors have written articles for (radio)pharmaceutical, med. device, biotechnology or consulting companies during the last 5 yrs. If yes, specify name/position/company/article/journal & co-authors.If not state "Nothing to disclose" : Nothing to disclose I herewith declare, that I submitted all relevant information below to the best of my knowledge : True
Additional (Complete): I agree: Yes I agree: Yes
Presentation Preference (Complete): Oral or Poster Status: Complete European Association of Nuclear Medicine Schmalzhofgasse 26, 1060 Vienna, Austria Phone +43-(0)1-890 44 27, Fax +43-(0)1-890 44 27-9 E-mail:
[email protected]
Leave OASIS Feedback
Powered by cOASIS, The Online Abstract Submission and Invitation System SM © 1996 - 2016 CTI Meeting Technology All rights reserved.
http://www.abstractsonline.com/cSubmit/SubmitPrinterFriendlyVersion.asp?ControlK... 22/04/2016
